Orion Signs a Collaborative Agreement with Newel Health to Develop ODD-403 for Chronic Pain
Shots:
- Orion Corporation and Newel Helth joined forces to enhance the development of Orion’s ODD-403 (Rohkea) as a digital therapeutic for the treatment of patients suffering from chronic pain or fear of movement & re-injury
- Under the terms of the agreement, Newel will receive the exclusive rights to develop, manufacture, and commercialize ODD-403 globally whereas Orion will receive milestones payments plus royalties from the sales of the product
- ODD-403 is a software-based medical device built for VR devices to deliver an immersive gamified therapeutic treatment program for patients suffering from chronic pain
Ref: Orion | Image: Orion
Related News:- Novartis Enters into a Four-Year Collaboration with Orionis Biosciences to Tackle Intractable Disease Targets
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
